(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

We describe a method for prospectively collecting real-time, longitudinal datasets evaluating central nervous system (CNS)-directed IGRT across a multinational pediatrics consortium.

Sara R. Alcorn, MD, MPH, Todd R. McNutt, PhD, Michael J. Chen, MD, Karen Dieckmann, MD, Ralph P. Ermoian, MD, Eric C. Ford, PhD, Shannon M. MacDonald, MD, Alexey V. Nechesnyuk, MD, Kristina Nilsson, MD, PhD, Rosangela C. Villar, MD, Brian A. Winey, PhD, Erik J. Tryggestad, PhD, Stephanie A. Terezakis, MD; The Johns Hopkins Hospital

Background: In the pediatric population, there is a lack of consensus regarding the optimal technique for use of image-guided radiotherapy (IGRT), with no published comprehensive comparison of practices across institutions. This may be due in part to difficulty in collecting and analyzing large datasets amassed using varying techniques and technologies across institutions internationally. We describe a method for prospectively collecting real-time, longitudinal datasets evaluating central nervous system (CNS)-directed IGRT across a multinational pediatrics consortium.

Materials and Methods: Nine international institutions with dedicated pediatric expertise agreed to participate in data collection and analysis of IGRT practices for patients aged ≤ 21 years treated to CNS sites. Two institutions use proton therapy for children, and all others use image-guided intensity-modulated radiation therapy (IG-IMRT). Key demographic and treatment variables of interest were prospectively identified by consortium members, and standardized assessment tools interfacing with the MOSAIQ™ radiation oncology information system (OIS) were produced to capture these variables. Institutions then entered data into the OIS-based assessment tools in real time as patients accrued and during treatment. Each institution was capable of accessing its corresponding full dataset for internal purposes, whereas software was developed to allow for subsets of de-identified data to be extracted and submitted to a central database for analysis. These data were accessed through a series of coded queries, and output was compared both within and across institutions. Descriptive statistics were calculated, and chi-square and linear regression analyses were performed.

Results: To date, this methodology has allowed for successful access to the prospectively identified dataset of 46 pediatrics patients from two photon- and one proton-treating institutions. While data collection for the remaining sites is ongoing, an estimated 500 pediatric patients will be accrued yearly across all institutions. Sample output for patients treated with photon therapy showed a median age of 11.6 (range: 3–20 yr) and baseline Karnofsky performance status (KPS) of 80 (range: 30–100), with treatment to a median dose of 54 Gy (range: 24–59.4 Gy) over 30 fractions (range: 12–33 fractions). From the dataset of 2,715 translational table shifts collected from 905 pretreatment cone-beam CTs, a mean translational table shift vector magnitude of 3 mm was calculated. The consortium dataset also allowed for hypothesis generation, with preliminary univariate analyses showing that use of anesthesia was significantly associated with table shift vector magnitudes that were less than the mean value of 3 mm (P = .021). Conversely, potential predictors, including age, gender, immobilization type, degree of surgical resection, concurrent chemotherapy, KPS, and planning target volume, did not reach statistical significance in the preliminary analyses.

Conclusions: We describe a method for prospective and real-time data collection that allows for analysis of large datasets of de-identified patient and treatment information across a consortium of multinational institutions. Given the scarcity of data to guide IGRT use in the pediatric population, such methodology provides a novel means for describing breadth of practice and establishing consensus recommendations for IGRT. To our knowledge, this is the first report of the successful deployment of such methodology for analysis of the pediatric population.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content